HepG2 Cell Resistance against Camptothecin from a Lysosomal Drug Delivery

Hoyeon Lee; Soojin Uhm; Jung-Won Shin; Hyun Mi Jeon; Sun Dongbang; Hyo Sung Jung; Yun-Cheol Na; Chulhun Kang; Jong Seung Kim

doi:10.1002/asia.201500913

HepG2 Cell Resistance against Camptothecin from a Lysosomal Drug Delivery

Chem Asian J. 2015 Dec;10(12):2695-700. doi: 10.1002/asia.201500913. Epub 2015 Oct 1.

Authors

Hoyeon Lee¹, Soojin Uhm², Jung-Won Shin¹, Hyun Mi Jeon¹, Sun Dongbang², Hyo Sung Jung², Yun-Cheol Na³, Chulhun Kang⁴, Jong Seung Kim⁵

Affiliations

¹ The School of East-West Medical Science, Kyung Hee University, Yongin, 446-701, Korea.
² Department of Chemistry, Korea University, Seoul, 136-701, Korea.
³ Omics System Research Team, Korea Basic Science Institute, 150 Bugahyeon-ro, Seodaemun-gu, Seoul, 120-140, Republic of Korea.
⁴ The School of East-West Medical Science, Kyung Hee University, Yongin, 446-701, Korea. [email protected].
⁵ Department of Chemistry, Korea University, Seoul, 136-701, Korea. [email protected].

PMID: 26373261
DOI: 10.1002/asia.201500913

Abstract

A galactose-appended drug delivery system released camptothecin (CPT) to lysosomes of HepG2 hepatoma cells, resulting in the cell resistance to the anticancer drug. We found that the resistance to CPT is caused by alteration of the drug release from the prodrug in lysosomes, emphasizing that the final delivery locations may critically influence drug efficacy.

Keywords: anticancer drugs; camptothecin; cancer; drug delivery; galactose.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents, Phytogenic / chemistry*
Antineoplastic Agents, Phytogenic / toxicity
Camptothecin / chemistry*
Camptothecin / toxicity
Cell Survival / drug effects
Drug Carriers / chemistry*
Galactose / chemistry
Hep G2 Cells
Humans
Lysosomes / metabolism*
Microscopy, Confocal
Spectrometry, Fluorescence

Substances

Antineoplastic Agents, Phytogenic
Drug Carriers
Galactose
Camptothecin